Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.
|Original language||English (US)|
|Number of pages||3|
|Journal||Cell Stem Cell|
|State||Published - Jul 1 2016|
ASJC Scopus subject areas
- Molecular Medicine
- Cell Biology